Full-Time

Director – Biostatistics

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

AI & Machine Learning
Biotechnology

Compensation Overview

$207.5k - $284kAnnually

Senior

No H1B Sponsorship

San Francisco, CA, USA

Requires onsite presence in San Francisco for four days per week.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
R
Requirements
  • PhD. in Biostatistics and 10+ years of relevant work experience, or M.S. in Biostatistics and 13+ years of relevant work experience
  • Hands-on Experience in INDs, NDAs, MAAs, or other regulatory submissions
  • In-depth knowledge of statistical methods for clinical trials
  • Knowledge of FDA, EMA, and ICH regulations and guidelines
  • Proficient in statistical programming (SAS and R)
  • Experience leading statistical efforts for multiple studies
  • Fluent in data standards, including SDTM and ADaM
  • Experience with outsourced statistical services provided by CROs
Responsibilities
  • As a biostatistics expert for VIR clinical programs you will provide strategic input to optimize trial designs in late phase registrational studies
  • You will work with internal and external statistical programming team members on the planning and execution of statistical deliverables
  • Conduct statistical simulations to ensure robust and efficient statistical designs and address identified or potential statistical issues arising with studies
  • Contribute to clinical protocol development, including authoring or review of the Statistics section and reviewing of other sections by applying statistical principles
  • Author or review the development of statistical analysis plans for clinical trials and oversee the development of tables, figures, and listings, and associated deliverables
  • Review electronic case report form (eCRF) designs to ensure data collection meets the requirements of statistical analyses
  • Perform QC/QA of statistical deliverables including validation of main analysis results
  • Contribute to clinical study reports, including authoring of statistical methods, and interpretation of study results
  • Accountable for assigned statistical activities to support IND/NDA/MAA or other regulatory submissions; provide review for required components of regulatory submissions including appropriate datasets, define files, reviewer's guides, and other relevant documents
  • Address statistical questions/comments from FDA and other regulatory agencies, or IRB/ECs
  • Lead standardization and process improvement efforts for Biostatistics function, and contribute to cross-functional process improvement efforts including the definition of biostatics templates and standards
  • Represent VIR regarding statistical issues in meetings with external parties including regulatory agencies and corporate partners
  • Support inspection readiness activities

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.

Company Stage

Grant

Total Funding

$640.6M

Headquarters

San Francisco, California

Founded

2016

Growth & Insights
Headcount

6 month growth

2%

1 year growth

5%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent bullish quarterly reports and increased analyst estimates suggest strong financial performance.
  • Significant investments, such as the $214,000 from Diversified Trust Co, indicate confidence in Vir's future prospects.
  • Presentations at high-profile conferences like J.P. Morgan's Annual Healthcare Conference and AASLD's The Liver Meeting® enhance Vir's visibility and credibility in the biotech community.

What critics are saying

  • Recent layoffs and facility shutdowns indicate potential financial instability and operational challenges.
  • The resignation of key executives, including the CFO and Chief Medical Officer, could lead to strategic and leadership uncertainties.

What makes Vir Biotechnology unique

  • Vir Biotechnology's focus on leveraging immunology expertise to engineer human antibodies into powerful medicines sets it apart from competitors.
  • Their rapid growth, as evidenced by being ranked the fastest-growing company in North America on the 2023 Deloitte Technology Fast 500, highlights their market impact.
  • Vir's ongoing Phase 2 trials for chronic hepatitis delta and B demonstrate their commitment to addressing unmet medical needs with innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement